Royalty Report: Drugs, Disease, Therapeutic – Collection: 233486

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Alzheimer’s disease
  • Assay
  • Hair loss
  • Dermatology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 233486

License Grant
For the Research Program License, Licensor grants, during the Research Term, a non-exclusive, worldwide license, without the right to sublicense, except to subcontractors as provided in this Agreement, under the Licensor Technology solely to perform Licensee’s obligations under the Research Program.

For the Evaluation License Grant, Licensor grants, during the Option Period, a non-exclusive, limited research-use only license, without the right to sublicense, except to subcontractors as provided in this Agreement, under the Licensor Technology solely to perform Preliminary Evaluation Work and Evaluation Studies as provided in this Agreement.

For the Muscarinic Product Development and Commercialization License, Licensor grants, during the Term, an exclusive, worldwide license, with the right to sublicense even through multiple tiers of sublicense, under Licensor Technology and Licensor’s interest in Joint Patents, to develop, make, have made, use, distribute, promote, sell, offer for sale, have sold, import, and export Muscarinic Products in the Muscarinic Field.

For the Fixed Co-Formulation Product Development and Commercialization Exclusive License, effective only upon exercise of the Option and payment in full of the Option Exercise Fee, Licensor grants, during the Term, an exclusive, worldwide license, with the right to sublicense even through multiple tiers of sublicense, under Licensor Technology to develop, make, have made, use, distribute, promote, sell, offer for sale, have sold, import, and export Fixed Co-Formulation Products in the Sleep Field. For the avoidance of doubt, the license granted excludes any license under Licensor Technology to develop, make, have made, use, distribute, promote, sell, offer for sale, have sold, import, and export N-Dealkylated Licensed Compound Metabolites, and any license under Licensor Technology containing claims directed only to N-Dealkylated Licensed Compound Metabolites.

For the Fixed Co-Formulation Product Development and Commercialization Non-Exclusive License, Licensor grants, during the Term, a non-exclusive, worldwide license, with the right to sublicense even through multiple tiers of sublicense, under Licensor Technology and any other Patents directed to N-Dealkylated Licensed Compound Metabolites that are Controlled by Licensor to develop, make, have made, use, distribute, promote, sell, offer for sale, have sold, import, and export Fixed Co-Formulation Products in the Sleep Field.

For the Grant of Option, Licensor grants an option, exercisable during the Final Evaluation Period with respect to one (1) Chosen Compound, to obtain an exclusive, worldwide license, with the right to sublicense, under the Licensor Technology to develop, make, have made, use, distribute, distribute for sale, promote, sell, offer for sale, have sold, or import Fixed Co-Formulation Products in the Sleep Field.

License Property
Licensor Patents shall mean all Patents that Licensor or any of its Affiliates Controls as of the Effective Date or during the Research Term that are necessary or useful for performance of the Research Program or the Evaluation, or for the development, manufacture, use, import, offer for sale, or sale of any Selected Muscarinic Compound, Licensed Compound or Product, but excluding the Joint Patents.

The Licensor Know-How, beyond the patents, during the research term, excludes any such information relating to Licensors compounds known as -103 and -104, -104 Analogs and/or Topical Eyecare Compounds, which is Confidential Information of Licensor.

Licensor Muscarinic Compounds shall mean any compound Controlled by Licensor on the Effective Date, the primary mode of action of which is [activity as a selective] allosteric modulator, agonist, or antagonist of any one (1) or more of the five (5) muscarinic receptor subtypes, including, without limitation, Licensors proprietary [m3 antagonists), but subject to exclusion of [m1] Agonists.  Notwithstanding the foregoing or any other provision of this Agreement to the contrary, neither Licensors compound known as -104 (N-desmethylclozapine) nor any -104 Analogs shall be considered Licensor Muscarinic Compounds for purposes of this Agreement.

Muscarinic receptors are receptors that respond to acetylcholine, a neurotransmitter in the central nervous system.

Field of Use
Muscarinic Field shall mean the treatment, prevention, or both, of any disease or disorder in humans, but excluding the prevention or treatment of ocular disease.

Sleep Field shall mean the treatment, prevention, or management, or any combination thereof, as a primary objective, of any condition, disturbance, disease, or disorder in humans the principal effect(s) of which are on sleep time, sleep quality, sleep onset, sleep architecture, or sleep maintenance, or to disrupt or disturb normal sleep or sleep patterns, including without limitation insomnia, including without limitation transient, chronic, primary, and secondary insomnia; jet lag; bruxism; breathing related sleep disorders, including without limitation sleep apnea; sleep terror disorders, including sleep terrors and pavor nocturnus; sleep walking disorders; sleep paralysis; circadian rhythm sleep disorders, including without limitation delayed sleep phase syndrome, and advanced phase sleep syndrome; shift work sleep disorder; sleep enuresis; sudden infant death syndrome; narcolepsy; periodic limb movement disorder; rapid eye movement behavior disorder; other parasomnias; and other dysomnias, and also including, without limitation, any such condition, disturbance, disease, or disorder where the treatment, prevention, or management, or any combination thereof, of any such condition, disturbance, disease, or disorder may result, as a secondary objective, in [improving cognitive function, alertness, physical dexterity, coordination, symptoms of fatigue, and other detrimental symptoms associated with or arising from any of the foregoing conditions, disturbances, diseases, or disorders.

IPSCIO Record ID: 237226

License Grant
For the VLA-4 License Grant,  Licensor grants to the Swiss Licensee an exclusive license in the Territory in the Field under the VLA-4 Patent Rights and to use the VLA-4 Know-How to discover, develop, make, have made, import, export, use, manufacture, have manufactured, distribute, market, promote, offer for sale and sell Licensed Compound(s) and/or Licensed Product(s). Licensor shall retain the right to use the YLA-4 Patent Rights and VLA-4 Know-How solely in connection with the Research Program.

For the VLA-4 Non-Exclusive License Grant,  in the event that the discovery, development, making, having made, importing, exporting, use, manufacturing, having manufactured, distribution, marketing, promotion, offering for sale or sale by Licensee, its Affiliates and/or sublicensees of Licensed Compound(s) and/or Licensed Product(s) would, during the term of this Agreement, infringe a claim of an issued letters patent, or any other patent rights which Licensor owns or has the rights to license and which patents are not covered by the grant, Licensor hereby grants, to the extent Licensor is legally able to do so, a non-exclusive license in the Territory under such issued letters patent solely for Licensee to discover, develop, make, have made, import, export, use, manufacture, have manufactured, distribute, market, promote, offer for sale and sell Licensed Compound(s) and/ or Licensed Product(s) in the Territory.

Licensor grants an exclusive option right to include under this Agreement an exclusive license in the Territory for the development and commercialization of Alpha-4-Beta-7 Compounds.

License Property
Licensed Compound(s) shall mean any VLA-4 Compound and, upon the Option Date, any Alpha-4-Beta-7 Compound owned or controlled by Licensor and/or any of its Affiliates as of the Effective Date or the Option Date, as the case may be, or discovered by or on behalf of Licensor and /or any of its Affiliates in performance of the Research Program during the Research Term or during the one (1) year period following the Research Term. In addition, Licensed Compound shall include any compounds claimed in VLA-4 Patent Rights and Alpha-4-Beta-7 – Patent Rights.
Field of Use
The Field shall mean the use of VLA-4 Compounds to treat or prevent any disease, disorder or condition in humans or animals.

VLA-4 antagonists represent a new class of compounds that has shown promise in multiple preclinical animal models of asthma. The primary focus of the collaboration will be to discover orally available VLA-4 antagonists as treatments for asthma.

IPSCIO Record ID: 239026

License Grant
For selected targets, Licensor grants to Licensee and its Affiliates, within the Territory, a non-exclusive right and license, without any right to sublicense, except as set forth below,  under Licensors rights in the Licensor Background Materials and the Licensor Background Technology and a co-exclusive right and license, without any right to sublicense, except as set forth below, under Licensors rights in the Program Intellectual Property to identify and validate Selected Targets, other than Selected Targets that have become Licensee Inactive Selected Targets, Licensor Inactive Selected Targets, Licensee Targets or Licensor Targets, for the identification, evaluation and optimization of Small Molecule Compounds that are active against such Selected Targets for use in the CNS Field,  identify Small Molecule Compounds that are active against such Selected Targets through the use of such Selected Targets and undertake preclinical research and evaluation of Program Compounds, in each case in the conduct of the Research Program.

For the Inactive Selective Targets, Licensor grants to Licensee and its Affiliates, within the Territory,  a non-exclusive right and license, without any right to sublicense, except as set forth below,  under Licensors rights in the Licensor Background Materials and the Licensor Background Technology and an exclusive right and license, without any right to sublicense, except as set forth below, under Licensors rights in the Program Intellectual Property to validate Licensee Inactive Selected Targets for the identification, evaluation and optimization of Small Molecule Compounds that are active against such Selected Targets for use in the CNS Field,  identify Small Molecule Compounds that are active against such Licensee Inactive Selected Targets through the use of such Licensee Inactive Selected Targets and undertake preclinical research and evaluation of Small Molecule Compounds that are active against such Licensee Inactive Selected Targets.

For the Licensee targets, Licensor grants to Licensee and its Affiliates, within the Territory,  a non-exclusive right and license, without any right to sublicense, except as set forth below, under Licensors rights in the Licensor Background Materials and the Licensor Background Technology and an exclusive right and license, without any right to sublicense, except as set forth below, under Licensors rights in the Program Intellectual Property to identify Small Molecule Compounds that are active against Licensee Targets through the use of such Licensee Targets and undertake preclinical research and evaluation of Small Molecule Compounds that are active against such Licensee Targets.

For the Grants of Development and Commercialization Licenses, Licensor grants to Licensee and its Affiliates, within the Territory, an exclusive right and license, with the right to sublicense, under Licensors rights in the Program Intellectual Property to develop, make, have made, import, use, have used, offer for sale, sell and have sold Licensee Development Compounds and Licensee Products.

License Property
Licensor is engaged in the identification and validation of targets for use in the discovery of compounds potentially useful to prevent or treat diseases and conditions of the central nervous system.

Small Molecule Compound means a chemical compound having a molecular weight of less than 1,000 Daltons, as well as conjugates of such chemical compounds to larger molecules to improve the delivery bioavailability and/or pharmacokinetic properties of such chemical compound.

Licensors Product means a pharmaceutical product containing a Licensor Development Compound as an active ingredient.

Selected Target means any Target that is selected for research by the Joint Management Committee.

Field of Use
Both Parties are each in the business of discovering, developing and commercializing pharmaceutical products.

CNS Field means the prevention, palliation, control or treatment in humans of depression, schizophrenia, bipolar disease, dementia, anxiety, attention deficit hyperactivity disorder, anorexia nervosa and other affective disorders, Alzheimers disease and other cognitive disorders, Parkinsons disease, amyotrophic lateral sclerosis and other neurodegenerative disorders, pain, epilepsy, insomnia, narcolepsy and other sleep disorders, substance abuse and migraine.

IPSCIO Record ID: 223127

License Grant
Licensor hereby grants to Licensee a non-transferable, exclusive license, with the limited right to sublicense, under the Licensor Compound Patent Rights solely to the extent necessary to Develop, make, have made, use, import, offer to sell, and Commercialize the Products in the Field in the Territory.

Licensor hereby grants to Licensee a non-transferable, nonexclusive license, with the limited right to sublicense, (a) under the Licensor Know How solely to the extent necessary to Develop, make, have made, use, import, offer to sell, and Commercialize the Products in the Field in the Territory, and (b) in the event Licensee enters into a Supply Agreement with a Third Party, under the Licensor Manufacturing Patents solely to the extent necessary to have made the Products or Compounds in the Field in the Territory for sale to Licensee.

License Property
Compounds means the compounds identified as BMS-214778 and BMS-330446.
BMS-214778 is a dihydrobenzofuranyl compound which is a melatonin receptor agonist.
BMS-330446 is a pyrrolidinyl derivative of BMS-214778 and is also a melatonin receptor agonist.

Product means any product or pharmaceutical formulation containing a Compound as one of its active ingredients (or as the sole active ingredient), in all dosage forms, formulations, presentations, line extensions, and package configurations.

BMS-214778
UseTreatment of sleep disorder; Melatonin receptor agonist

Field of Use
This agreement pertains to the drug industry relating to the field which means the application to any human disease, disorder or condition, including without limitation sleep disorders such as insomnia and disorders of circadian rhythm.

IPSCIO Record ID: 336363

License Grant
For the License Grants for Collaborative Research, Licensor grants an exclusive, worldwide, non-transferable, except as to Japan, license, with the right to sublicense only as it relates to Japan, under the Licensor Technology and Licensors interest in the Collaboration Technology to use such technology solely to the extent necessary or appropriate to carry out Allergans research responsibilities under the Collaboration in the Field.

For the License Grant for Development and Commercial Purposes, Licensor grants the following rights and licenses
–  an exclusive, license under the Licensor Technology and Licensor’s interest in the Collaboration Technology to make, have made, and use Collaboration Lead Compounds in order to conduct necessary preclinical, clinical and other development activities on such Collaboration Lead Compounds to obtain Regulatory Approval for use in the Field as Licensee Products;
–  an exclusive license under the Licensor Technology and Licensor’s interest in the Collaboration Technology to make, have made, use and sell Licensees Products in the Field in the Territory.

License Property
Licensor has discovered compounds that are potent agonists selective for the m1 muscarinic receptor which agonists may be useful in the treatment of ocular disease such as glaucoma.

The patent is titled Compounds with Activity on Muscarinic Receptors.

Licensor Designated Compound shall mean any one of up to ten Active Compounds and their respective enantiomers and isomers, to the extent such isomers are included in the mixture tested and salts thereof,

Licensor Know-How shall mean all tangible or intangible know-how, trade secrets, inventions, whether or not patentable, data, preclinical results, physical, chemical or biological material, and other information and data on or relating to all M1 Muscarinic.

Active Compounds shall mean any M1 Muscarinic that demonstrates the requisite activity levels in the Assays pursuant to the Research Plan

M1 Muscarinics shall mean all m1 muscarinic receptor ligands in Licensor’s possession as of the Effective Date, synthesized during the Research Term pursuant to the Research Plan or in any other Licensor program which selectively targets activation of the m1 muscarinic receptor, or acquired from Third Parties during the Research Term pursuant to the Research Plan or in conjunction with any other Licensor program which selectively targets activation of the m1 muscarinic receptor.

Assays shall mean R-SATâ„¢ assays used to measure activity at all muscarinic receptors and other in vitro molecular assays as determined by the RMC.

Field of Use
The Field shall mean the prevention or treatment of ocular disease.

IPSCIO Record ID: 239605

License Grant
For grant of research license, for Selected Targets, Licensor grants to Licensee and its Affiliates, within the Territory,  a non-exclusive right and license, without any right to sublicense, except as set forth below, under Licensors rights in the Licensor Background Materials and the Licensor Background Technology and a co-exclusive right and license,without any right to sublicense, except as set forth below, under Licensor s rights in the Program Intellectual Property to identify and validate Selected Targets, other than Selected Targets that have become Licensor Inactive Selected Targets, Licensee Inactive Selected Targets, Licensor Targets or Licensee Targets, for the identification, evaluation and optimization of Small Molecule Compounds that are active against such Selected Targets for use in the CNS Field,  identify Small Molecule Compounds that are active against such Selected Targets through the use of such Selected Targets and undertake preclinical research and evaluation of Program Compounds, in each case in the conduct of the Research Program.

For Licensee Inactive Selected Targets,  Licensor hereby grants to Licensee and its Affiliates, within the Territory, a non-exclusive right and license, without any right to sublicense, except as set forth below, under Licensors rights in the Licensor Background Materials and the Licensor Background Technology and an exclusive right and license (without any right to sublicense, except as set forth below) under Licensors rights in the Program Intellectual Property to validate Licensee Inactive Selected Targets for the identification, evaluation and optimization of Small Molecule Compounds that are active against such Selected Targets for use in the CNS Field, identify Small Molecule Compounds that are active against such Licensee Inactive Selected Targets through the use of such Licensee Inactive Selected Targets and undertake preclinical research and evaluation of Small Molecule Compounds that are active against such Licensee Inactive Selected Targets.

For the Licensee Targets, Licensor grants to Licensee and its Affiliates, within the Territory,  a non-exclusive right and license, without any right to sublicense, except as set forth below, under Licensors rights in the Licensor Background Materials and the Licensor Background Technology and an exclusive right and license, without any right to sublicense, except as set forth below, under Licensors rights in the Program Intellectual Property to identify Small Molecule Compounds that are active against Licensee Targets through the use of such Licensee Targets and undertake preclinical research and evaluation of Small Molecule Compounds that are active against such Licensee Targets.

For the Grants of Development and Commercialization Licenses. Licensor grants to Licensee and its Affiliates, within the Territory, an exclusive right and license, with the right to sublicense, under Licensors rights in the Program Intellectual Property to develop, make, have made, import, use, have used, offer for sale, sell and have sold Licensee Development Compounds and Licensee Products.

License Property
Small Molecule Compound means a chemical compound having a molecular weight of less than 1,000 Daltons, as well as conjugates of such chemical compounds to larger molecules to improve the delivery bioavailability and/or pharmacokinetic properties of such chemical compound.

Licensors Product means a pharmaceutical product containing a Licensor Development Compound as an active ingredient.

Selected Target means any Target that is selected for research by the Joint Management Committee.

Field of Use
Both Parties are each in the business of discovering, developing and commercializing pharmaceutical products.

CNS Field means the prevention, palliation, control or treatment in humans of depression, schizophrenia, bipolar disease, dementia, anxiety, attention deficit hyperactivity disorder, anorexia nervosa and other affective disorders, Alzheimers disease and other cognitive disorders, Parkinsons disease, amyotrophic lateral sclerosis and other neurodegenerative disorders, pain, epilepsy, insomnia, narcolepsy and other sleep disorders, substance abuse and migraine.

IPSCIO Record ID: 279348

License Grant
Licensor grants
—  during the Research Term, a non-exclusive, worldwide, license, without the right to sublicense, under the Licensor Technology solely to perform Licensees obligations under the Research Plan; and
—  an exclusive, worldwide license, including the right to sublicense, under the Licensor Technology and Licensors interest in the Joint Patent Rights, to develop, make, have made, use, sell, have sold, offer for sale and import Selected Compounds and Products solely in the Licensee Field.
License Property
Licensor possesses scientific and proprietary technology and data and resources relating to the Hedgehog Pathway.  Hedgehog Pathway shall mean the biological signaling cascade which stimulates the transcription of various genes that mediate Hedgehog-dependent phenotypic cellular changes, as evidenced by the upregulation of transcription of Gli.

Product shall mean any final dosage form of a pharmaceutical product containing a Selected Compound for use in the Licensee Field.

Field of Use
Licensee possesses scientific and technical resources relating to the development and commercialization of pharmaceutical products for the treatment of skin diseases and/or disorders or for the promotion of hair growth in humans.

Licensor Field shall mean the local administration of Excluded Compounds for
—  the treatment or prevention of cardiovascular diseases and disorders in humans, including but not limited to the use of an Excluded Compound coated on a cardiovascular stent and ex vivo use of Excluded Compounds for the preparation of cells to be used in cell therapy applications; and/or any other indication in humans (excluding any indication within the Licensee Field) to which Licensor obtains rights from Third Party after the Effective Date; and/or
—  the Veterinary Field.  Veterinary Field shall mean Topical Application of a Licensed Compound for the treatment or prevention of any skin disease or disorder in animals, excluding humans.

Licensee Field shall mean the Topical Application of a Selected Compound or Product for the promotion of hair growth in humans (Hair Growth lndications); and/or any other indication in which Topical Application is used in humans – each, a Skin-Related Indication.

IPSCIO Record ID: 204310

License Grant
This agreement is for the reversion to Licensee of the rights for the Commercialization of Compound and Products in the United States, including the rights to Commercialize Co-Formulation Products in the United States.

The Licensor of England grants back to Licensee the following licenses, with the right to grant sublicenses, under all Program Improvements and Program Patents  
(i) a co-exclusive license to Develop Products in the Field and in the Territory,
(ii) subject to Licensor’s rights and obligations to Manufacture Products for Development activities, an exclusive license, exclusive even as to Licensor, to make and have made and otherwise Manufacture Compound and Products, other than Co-Formulation Products, in the Field and anywhere in the Territory for the Licensee Territory; and
(iii) an exclusive license, exclusive even as to Licensor, to use, sell, offer for sale, import and otherwise Commercialize Products in the Field in the Licensee Territory.

Licensor grants the following licenses, with the right to grant sublicenses, under the Co-Formulation Product IP
(i) a co-exclusive license to Develop Co-Formulation Products in the Field in the Territory, and
(ii) an exclusive license, exclusive even as to Licensor, to use, sell, offer for sale, import and otherwise Commercialize Co-Formulation Products in the Field in the Amicus Territory.

Licensor grants to Licensee a worldwide, non-exclusive, right and license, with the right to grant sublicenses,
(a) under Licensor’s and its Affiliates’ rights in the Program Patents to make, have made, use, sell, offer for sale, and import products, and to otherwise practice and exploit the Program Improvements and
(b) under Licensor’s and its Affiliates’ rights in the Patents within the Co-Formulation Product IP to make and have made, other than JR051 or Co-Formulation Product in which the ERT enzyme is JR051, use, sell, offer for sale and import products, other than JR051, and to otherwise practice and exploit the Patents within the Co-Formulation Product IP claimed in such Program Patents and/or Patents within the Co-Formulation Product IP.

In the original agreement, Amicus granted to Licensee exclusive, worldwide, rights to Compounds and Products (each as defined below) and pursuant to which Amicus and GSK have collaborated and are collaborating on the Development of the Compound and Product;

License Property
The Compound means migalastat, and includes (a) any compounds with alternative names but with the same chemical structure as migalastat, and (b) any metabolites, prodrugs, isomers and enantiomers, excluding the isomer/enantiomer 1-deoxynorjirimycin or (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol, esters, salts, hydrates, solvates, and polymorphs thereof, whether alone or in a mixture.

The Co-Formulation Product ERT Enzyme means JR051; or any other alpha Galactosidase A enzyme selected by the Parties to be used as a ERT enzyme in co-formulation with the Compound.  ERT means enzyme replacement therapy.

Co-development of all current and future formulations of migalastat HCl for Fabry disease, including a co-formulation of migalastat HCl with Licensee’s investigational enzyme replacement therapy (ERT) for Fabry disease.

Fabry disease is a rare genetic disease a deficiency of the enzyme alpha-galactosidase A (a-Gal A) that causes a buildup of a type of fat called globotriaosylceramide (Gb3, or GL-3) in the body. Fabry disease is classified as a type of lysosomal storage disorder.

Field of Use
The Field means any and all uses or purposes, including, without limitation, the treatment, palliation, and/or prevention and diagnosis of any human or animal disease, disorder or condition, including use of a Product in combination with ERT.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.